This Article Full Text Full Text (PDF) All Versions of this Article: 0192623309339605v1 37/5/629    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zhang, J. Articles by Hanig, J. P. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. Articles by Hanig, J. P. Social Bookmarking                         What's this?

Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-, and Valproic Acid-Treated Rats: Potential Role of iNOS and Nitrotyrosine

¹ Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
² Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland, USA
³ Argutus Medical Ltd., Dublin, Ireland
⁴ Harvard Institutes of Medicine, Renal Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Address correspondence to: Jun Zhang, M.D., M.S., Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration (HFD-910), 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, U.S.A.; e-mail:jun.zhang{at}fda.hhs.gov.

The present study compared the immunolocalization of Kim-1, renal papillary antigen (RPA)-1, and RPA-2 with that of inducible nitric oxide synthase (iNOS) and nitrotyrosine in kidneys of gentamicin sulfate (Gen)- and cisplatin (Cis)-treated rats. The specificity of acute kidney injury (AKI) biomarkers, iNOS, and nitrotyrosine was evaluated by dosing rats with valproic acid (VPA). Sprague-Dawley (SD) rats were injected subcutaneously (sc) with 100 mg/kg/day of Gen for six or fourteen days; a single intraperitoneal (ip) dose of 1, 3, or 6 mg/kg of Cis; or 650 mg/kg/day of VPA (ip) for four days. In Gen-treated rats, Kim-1 was expressed in the epithelial cells, mainly in the S1/S2 segments but less so in the S3 segment, and RPA-1 was increased in the epithelial cells of collecting ducts (CD) in the cortex. Spatial expression of iNOS or nitrotyrosine with Kim-1 or RPA-1 was detected. In Cis-treated rats, Kim-1 was expressed only in the S3 segment cells, and RPA-1 and RPA-2 were increased in the epithelial cells of medullary CD or medullary loop of Henle (LH), respectively. Spatial expression of iNOS or nitrotyrosine with RPA-1 or RPA-2 was also identified. These findings suggest that peroxynitrite formation may be involved in the pathogenesis of Gen and Cis nephrotoxicity and that Kim-1, RPA-1, and RPA-2 have the potential to serve as site-specific biomarkers for Gen or Cis AKI.

Key Words: cisplatin • gentamicin • Kim-1 • nitrotyrosine • RPA-1 • RPA-2

Abbreviations: AKI, acute kidney injury • CD, collecting ducts • Cis, cisplatin • DCT, distal convoluted tubule • Gen, gentamicin sulfate • IHC, immunohistochemistry • iNOS, inducible nitric oxide synthase • Kim-1, kidney injury molecule-1 • LH, loop of Henle • NO, nitric oxide • RPA-1, renal papillary antigen-1 • RPA-2, renal papillary antigen-2 • S1/S2 segments, proximal convoluted tubules • S3 segment, proximal straight tubules • VPA, valproic acid

This version was published on August 1, 2009

Toxicologic Pathology, Vol. 37, No. 5, 629-643 (2009)
DOI: 10.1177/0192623309339605


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?